Skip to main content
Signal8
Launch Terminal

Lucid Diagnostics Inc. (LUCD)

Lucid Diagnostics Inc. is a commercial-stage medical technology firm focused on diagnostic solutions. The company's primary objective is to serve patients afflicted with gastroesophageal reflux disease (GERD), commonly referred to as chronic heartburn or acid reflux, especially those at increased risk of developing precancerous esophageal conditions or the particularly aggressive esophageal adenocarcinoma. Their key product offerings include EsoGuard, an internally developed esophageal DNA test, and EsoCheck, a specialized device designed for collecting esophageal cells. Formed in 2018, Lucid Diagnostics Inc. has its headquarters in New York, New York, and operates as a subsidiary of PAVmed Inc.

Sector: Surgical & Medical Instruments & Apparatus

Industry: Medical - Devices

Lucid Diagnostics Inc. logo

Lucid Diagnostics Inc.

NASDAQ:LUCDHealthcare
-6.36%$0.4048
AH$0.4038-0.25%vs close
Mkt Cap$82.27M
Float–
O/S203.24M
Vol
$ Vol
RVOL
Inst Own30.2%
Earnings
Dilution
Lucid Diagnostics Inc. logoNASDAQ:LUCD$0.4048-6.36%
Phase Distribution
8 lead-sponsored trials·2 active·5 completed
Not applicable8
(5 more as collaborator)
Status Overview
Recruiting1
Active, not recruiting1
Completed5
Stopped1

Trials need funding. See this company's dilution risk and cash position.

Clinical Trials
Sponsor role
Status
  • Not applicable
    Completed

    In Vivo Confocal Microscopy for Pigmented Lesion Diagnosis

    Reflectance confocal microscopy

    Skin Cancer, Melanoma +1

    Enrollment
    441
    Start
    Aug 2008
    Primary Completion
    Dec 2009
    Completion
    Dec 2009
    NCT00785369
  • Observational
    Withdrawn

    VivaNet Study. A Multicenter Study of Confocal Reflectance Microscopy in Telemedicine

    -

    Skin Cancer, Skin Lesions

    Enrollment
    0
    Start
    Apr 2011
    Primary Completion
    Dec 2015
    Completion
    Dec 2015
    NCT01385943
  • Not applicable
    Completed

    Efficacy of EsoGuard on Samples Collected Using EsoCheck Versus EGD for the Diagnosis of BE

    EsoGuard

    Barrett Esophagus, Esophageal Adenocarcinoma +2

    Enrollment
    145
    Start
    Feb 2020
    Primary Completion
    Aug 2022
    Completion
    Aug 2022
    NCT04293458
  • Not applicable
    Active, not recruiting

    Efficacy of EsoGuard Assay on Esophageal Surface Cells Collected With EsoCheck vs EGD for the Diagnosis of BE or EAC

    EsoGuard (lab assay), Esophagogastroduodenoscopy

    Barrett Esophagus, Esophageal Adenocarcinoma +2

    Enrollment
    784
    Start
    Jun 2020
    Primary Completion
    Jun 2027est.
    Completion
    Jun 2027est.
    NCT04295811
  • Not applicable
    Completed

    Clinical Utility of a Non Endoscopic Device EsoCheck and Biomarker EsoGuard as Alternative to Endoscopy for Screening for Barrett's Esophagus in At Risk Population

    EsoGuard result

    Barrett Esophagus

    Enrollment
    97
    Start
    Apr 2023
    Primary Completion
    Jul 2024
    Completion
    Aug 2024
    NCT05778851
  • Not applicable
    Completed

    The Effect of Auditory Interventions on Anxiety and Agitation in People With Dementia

    Music and Theta Auditory Beat Stimulation, Audiobooks

    Mild to Moderate Dementia

    Enrollment
    48
    Start
    May 2023
    Primary Completion
    Aug 2023
    Completion
    Aug 2023
    NCT05844241
  • Observational
    Recruiting

    Lucid Registry Study

    EsoCheck®, EsoGuard®

    Barrett Esophagus, Esophageal Adenocarcinoma +2

    Enrollment
    8,000
    Start
    Apr 2023
    Primary Completion
    Dec 2027est.
    Completion
    Dec 2027est.
    NCT05965999
  • Not applicable
    Completed

    CLUE: CLinical Utility Study of EsoGuard

    EsoGuard

    Barrett Esophagus, Barretts Esophagus With Dysplasia +1

    Enrollment
    566
    Start
    Feb 2023
    Primary Completion
    Dec 2024
    Completion
    Dec 2024
    NCT06030180
Search ClinicalTrials.gov for “Lucid Diagnostics”